Background: Diet is known to play a major role in Crohn's disease (CD). It has also been reported that the minor G allele from the rs12212067 polymorphism (T>G) in FOXO3 is associated with milder CD. The aim of this study was to investigate the association between the rs12212067 polymorphism and food intolerances for a total of 253 foods. Methods: Tolerances and intolerances were recorded on a self-reported dietary questionnaire. Each food was scored on a 5-point ordinal scale: beneficial effects as ‘+ +' or ‘+', adverse effects as ‘- -' or ‘-', and ‘makes no difference' as ‘='. Dietary and genotype data were available for a total of 283 CD patients. Results: We identified 17 foods with beneficial effects in our study which were significantly associated with the G allele of the FOXO3 rs12212067 polymorphism. Of these, sweet potatoes had the highest reported frequency of beneficial responses. We also identified 4 foods with detrimental effects in more than 25% of our study population. These were mustard, wasabi, and raw and cooked tomatoes, which again were significantly associated with the G allele in FOXO3. Conclusions: There was strong evidence that adverse effects of mustard, wasabi, and raw and cooked tomatoes were significantly associated with the G allele of FOXO3 and that these foods should be avoided by people carrying this allele.

Keywords:
FOXO3, Crohnߣs disease, Diet, Tolerance, Intolerance
1.
Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-434.
2.
Paul G, Khare V, Gasche C: Inflamed gut mucosa: downstream of interleukin-10. Eur J Clin Invest 2012;42:95-109.
3.
Cooney R, Jewell D: The genetic basis of inflammatory bowel disease. Dig Dis 2009;27:428-442.
4.
Reiff C, Kelly D: Inflammatory bowel disease, gut bacteria and probiotic therapy. Int J Med Microbiol 2010;300:25-33.
5.
Jostins L, Ripke S, Weersma RK, et al: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-124.
6.
Loftus EV Jr, Sandborn WJ: Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:1-20.
7.
Franke A, McGovern DP, Barrett JC, et al: Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-1125.
8.
Lees CW, Barrett JC, Parkes M, Satsangi J: New IBD genetics: common pathways with other diseases. Gut 2011;60:1739-1753.
9.
Geier MS, Butler RN, Howarth GS: Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol 2007;115:1-11.
10.
Shanahan F: Probiotics in inflammatory bowel disease - therapeutic rationale and role. Adv Drug Deliv Rev 2004;56:809-818.
11.
Amre DK, D'Souza S, Morgan K, Seidman G, Lambrette P, Grimard G, Israel D, Mack D, Ghadirian P, Deslandres C, Chotard V, Budai B, Law L, Levy E, Seidman EG: Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. Am J Gastroenterol 2007;102:2016-2025.
12.
Sakamoto N, Kono S, Wakai K, Fukuda Y, Satomi M, Shimoyama T, Inaba Y, Miyake Y, Sasaki S, Okamoto K, Kobashi G, Washio M, Yokoyama T, Date C, Tanaka H: Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis 2005;11:154-163.
13.
Day AS, Whitten KE, Lemberg DA, Clarkson C, Vitug-Sales M, Jackson R, Bohane TD: Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach. J Gastroenterol Hepatol 2006;21:1609-1614.
14.
Triggs CM, Munday K, Hu R, Fraser AG, Gearry RB, Barclay ML, Ferguson LR: Dietary factors in chronic inflammation: food tolerances and intolerances of a New Zealand Caucasian Crohn's disease population. Mutat Res 2010;690:123-138.
15.
Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW, Koenderman L, Coffer PJ: Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27KIP1. Mol Cell Biol 2000;20:9138-9148.
16.
Medema RH, Kops GJ, Bos JL, Burgering BM: AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000;404:782-787.
17.
Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ Jr, DiStefano PS, Chiang LW, Greenberg ME: DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 2002;296:530-534.
18.
Ogg S, Paradis S, Gottlieb S, Patterson GI, Lee L, Tissenbaum HA, Ruvkun G: The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature 1997;389:994-999.
19.
Furukawa-Hibi Y, Yoshida-Araki K, Ohta T, Ikeda K, Motoyama N: FOXO forkhead transcription factors induce G2-M checkpoint in response to oxidative stress. J Biol Chem 2002;277:26729-26732.
20.
Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH, Burgering BM: Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 2002;419:316-321.
21.
Nemoto S, Finkel T: Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 2002;295:2450-2452.
22.
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-868.
23.
Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ: Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000;10:1201-1204.
24.
Accili D, Arden KC: FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004;117:421-426.
25.
Dejean AS, Beisner DR, Ch'en IL, Kerdiles YM, Babour A, Arden KC, Castrillon DH, DePinho RA, Hedrick SM: Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells. Nat Immunol 2009;10:504-513.
26.
Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KE, Sklavos MM, Ambs S, Yagita H, Hurwitz AA: FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest 2011;121:1361-1372.
27.
Lee JC, Espeli M, Anderson CA, Linterman MA, Pocock JM, Williams NJ, Roberts R, Viatte S, Fu B, Peshu N, Hien TT, Phu NH, Wesley E, Edwards C, Ahmad T, Mansfield JC, Gearry R, Dunstan S, Williams TN, Barton A, Vinuesa CG, Parkes M, Lyons PA, Smith KG: Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 2013;155:57-69.
28.
Gregersen PK, Manjarrez-Orduno N: FOXO in the hole: leveraging GWAS for outcome and function. Cell 2013;155:11-12.
29.
Marlow GJ, van Gent D, Ferguson LR: Why interleukin-10 supplementation does not work in Crohn's disease patients. World J Gastroenterol 2013;19:3931-3941.
30.
Goyette P, Boucher G, Mallon D, Ellinghaus E, Jostins L, Huang H, Ripke S, Gusareva ES, Annese V, Hauser SL, Oksenberg JR, Thomsen I, Leslie S, Daly MJ, Van Steen K, Duerr RH, Barrett JC, McGovern DP, Schumm LP, Traherne JA, Carrington MN, Kosmoliaptsis V, Karlsen TH, Franke A, Rioux JD: High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet 2015;47:172-179.
31.
Balding DJ: A tutorial on statistical methods for population association studies. Nat Rev Genet 2006;7:781-791.
32.
Grzanna R, Lindmark L, Frondoza CG: Ginger - an herbal medicinal product with broad anti-inflammatory actions. J Med Food 2005;8:125-132.
33.
Oyagbemi AA, Saba AB, Azeez OI: Molecular targets of [6]-gingerol: its potential roles in cancer chemoprevention. Biofactors 2010;36:169-178.
34.
Chakraborty D, Bishayee K, Ghosh S, Biswas R, Mandal SK, Khuda-Bukhsh AR: [6]-Gingerol induces caspase 3 dependent apoptosis and autophagy in cancer cells: drug-DNA interaction and expression of certain signal genes in HeLa cells. Eur J Pharmacol 2012;694:20-29.
35.
Kim EC, Min JK, Kim TY, Lee SJ, Yang HO, Han S, Kim YM, Kwon YG: [6]-Gingerol, a pungent ingredient of ginger, inhibits angiogenesis in vitro and in vivo. Biochem Biophys Res Commun 2005;335:300-308.
36.
Nigam N, George J, Srivastava S, Roy P, Bhui K, Singh M, Shukla Y: Induction of apoptosis by [6]-gingerol associated with the modulation of p53 and involvement of mitochondrial signaling pathway in B[a]P-induced mouse skin tumorigenesis. Cancer Chemother Pharmacol 2010;65:687-696.
37.
Antonious GF, Bomford M, Vincelli P: Screening Brassica species for glucosinolate content. J Environ Sci Health B 2009;44:311-316.
38.
Uto T, Hou DX, Morinaga O, Shoyama Y: Molecular mechanisms underlying anti-inflammatory actions of 6-(methylsulfinyl)hexyl isothiocyanate derived from wasabi (Wasabia japonica). Adv Pharmacol Sci 2012;2012:614046.
39.
Oliveira CP, Kassab P, Lopasso FP, Souza HP, Janiszewski M, Laurindo FR, Iriya K, Laudanna AA: Protective effect of ascorbic acid in experimental gastric cancer: reduction of oxidative stress. World J Gastroenterol 2003;9:446-448.
40.
Salman H, Bergman M, Djaldetti M, Bessler H: Lycopene affects proliferation and apoptosis of four malignant cell lines. Biomed Pharmacother 2007;61:366-369.
41.
Strimpakos AS, Sharma RA: Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008;10:511-545.
42.
Ferguson LR: Meat and cancer. Meat Sci 2010;84:308-313.
43.
Li W, Zhang J, Yu C, Li Q, Dong F, Wang G, Gu G, Guo Z: Extraction, degree of polymerization determination and prebiotic effect evaluation of inulin from Jerusalem artichoke. Carbohydr Polym 2015;121:315-319.
44.
Kim KA, Gu W, Lee IA, Joh EH, Kim DH: High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS One 2012;7:e47713.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.